Immucell (ICCC) Cash & Equivalents (2016 - 2025)
Immucell (ICCC) has disclosed Cash & Equivalents for 16 consecutive years, with $3.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Cash & Equivalents rose 2.04% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Sep 2025, up 2.04%, and an annual FY2024 reading of $3.8 million, up 283.99% over the prior year.
- Cash & Equivalents was $3.9 million for Q3 2025 at Immucell, down from $6.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $11.8 million in Q1 2022 and bottomed at $960347.0 in Q1 2024.
- Average Cash & Equivalents over 5 years is $5.4 million, with a median of $4.2 million recorded in 2025.
- The sharpest move saw Cash & Equivalents crashed 86.83% in 2023, then skyrocketed 378.93% in 2025.
- Year by year, Cash & Equivalents stood at $10.2 million in 2021, then tumbled by 43.14% to $5.8 million in 2022, then tumbled by 83.1% to $978741.0 in 2023, then skyrocketed by 283.99% to $3.8 million in 2024, then increased by 3.4% to $3.9 million in 2025.
- Business Quant data shows Cash & Equivalents for ICCC at $3.9 million in Q3 2025, $6.0 million in Q2 2025, and $4.6 million in Q1 2025.